Immutep Ltd · ASX:IMM

Immutep — Prima BioMed — SITC 2016 (Society for Immunotherapy of Cancer), National Harbor, MD

5 slides from Immutep's conference presentation, Nov 14, 2016

  1. Slide 1: An APC activator (IMP321 or LAG-3Ig) combined with anti-PD-1 blockade

    SITC 2016 NATIONAL HARBOR, MD NOVEMBER 9-13, 2016 An APC activator (IMP321 or LAG-3Ig) combined with anti-PD-1 blockade Frédéric Triebel, M.D., PhD. , Prima Biomed Ltd sitc Society for Immunotherapy of Cancer #SITC2016

  2. Slide 2: Three groups of patients responding to anti-PD-1

    SITC 2016 sitc Society for Immunotherapy of Cancer Three groups of patients responding to anti-PD-1 (IFN-y signature) A- Inflamed responders – respond to anti-PD-1 B- Inflamed non-responders (some infiltrates in the tumor margins but no response) C- Non inflamed. “Cold tumor” with no response Optima

  3. Slide 3: IMP321 induces a better Tc1 differentiation than sCD40L or TLR agonists

    SITC 2016 sitc Society for Immunotherapy of Cancer IMP321 induces a better Tc1 differentiation than sCD40L or TLR agonists Human blood lymphocytes are analyzed in a 16 hr ex vivo assay Intracellular staining of CD8 T cells Only IMP321 induces IFN+ CD8 T cell responses TLR agonists but not IMP321 ind

  4. Slide 4: In vitro and in vivo preclinical data supporting the combination

    SITC 2016 sitc Society for Immunotherapy of Cancer In vitro and in vivo preclinical data supporting the combination CMV-stimulated PBMCs from 10 healthy donors after 48hrs 7 6 IFN-y secretion (fold increase) 5 4 3 2 1 0 IMP321 (ng/ml) 0 30 30 0 Anti-PD-1 (ng/ml) 30 0 30 1000 Anti-PD-1 (10 mg/kg) + m

  5. Slide 5: TACTI-mel: Two ACTive Immunotherapeutics in melanoma

    SITC 2016 sitc Society for Immunotherapy of Cancer TACTI-mel: Two ACTive Immunotherapeutics in melanoma Phase I study in immuno-immuno combination in unresectable or metastatic melanoma in Australia up to 24 patients, 3 cohorts, max. 8 patients each IMP321 + anti-PD-1 (Keytruda) Multicenter, open la

Prima BioMed — SITC 2016 (Society for Immunotherapy of Cancer), National Harbor, MD on 6ix